India, May 28 -- RenovoRx, Inc. (RNXT), a life sciences company, announced Thursday that the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug Designation (ODD) for oxaliplatin for the treatment of pancreatic cancer. Oxaliplatin is an approved and commonly used chemotherapy.
This is RenovoRx's second ODD in pancreatic cancer, and third designation in total, reflecting the Company's differentiated approach to targeted intra-arterial drug-delivery using RenovoCath.
RenovoRx previously received ODD for intra-arterial gemcitabine delivered via RenovoCath in locally advanced pancreatic cancer (LAPC) and bile duct cancer.
This designation for oxaliplatin, a platinum-based chemotherapy widely used in pancreatic cancer treatme...